Johnson & Johnson vs Prologis Inc — how do they compare? Johnson & Johnson trades at $260.62 (market cap $626.09B), while Prologis Inc trades at $140.02 (market cap $132.57B). The key difference: Johnson & Johnson is far larger — about 4.7× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| JNJ | PLD | |
|---|---|---|
Market Cap | $626.09B | $132.57B |
Volume | 6,156,228 | — |
Sector | Health | Real Estate |
52-Week High | $267.24 | $149.96 |
52-Week Low | $172.78 | $104.81 |
Enterprise Value | $654.37B | $167.31B |
Dividend Yield | 2.06% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Prologis (PLD) trades at $139.75, up 0.74% today, with strong recent earnings beats but a bearish technical signal. The company announced a major $18.8 billion acquisition of SEGRO, expanding its European footprint, while financials show robust profitability with a 45.79% net income margin. Cash flow trends are mixed, with 2025 showing a net outflow but a projected recovery in 2026.
The outlook is positive due to strategic growth via acquisition and consistent earnings outperformance, though risks include integration challenges from the SEGRO deal and a high P/E ratio of 31.07. Analyst consensus is bullish with a $159.22 price target, suggesting significant upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →